Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics to Spotlight Oncolytic Virus Pipeline at Upcoming Investor Conference (CADL)
01:02am, Monday, 09'th Mar 2026
Error: Response status code does not indicate success: 400 (Bad Request). About Candel Therapeutics (NASDAQ: CADL) Candel Therapeutics (NASDAQ: CADL) is a clinical-stage immuno-oncology company focuse
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Mar 2026
NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologi
Paul Manning Buys 550,458 Shares of Candel Therapeutics (NASDAQ:CADL) Stock
04:22am, Saturday, 28'th Feb 2026
Candel Therapeutics, Inc. (NASDAQ: CADL - Get Free Report) Director Paul Manning purchased 550,458 shares of Candel Therapeutics stock in a transaction dated Monday, February 23rd. The stock was bough
Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston
08:05am, Tuesday, 24'th Feb 2026
NEEDHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Recommendation of “Moderate Buy” by Brokerages
04:10am, Saturday, 21'st Feb 2026
Shares of Candel Therapeutics, Inc. (NASDAQ: CADL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the stock, MarketBeat
Candel Therapeutics prices $100M public offering
08:42am, Friday, 20'th Feb 2026
Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at $5.45 per share. The clinical-stage biopharmaceu
US Supreme Court rules against Trump’s tariffs, raising questions for trade policy
06:56am, Friday, 20'th Feb 2026
The US Supreme Court has ruled that former President Donald Trump exceeded his authority by imposing broad tariffs on Canada, Mexico, and other countries...
Why Is Candel Therapeutics Stock Falling Friday?
05:55am, Friday, 20'th Feb 2026
Candel Therapeutics stock down on public offering pricing, intends to use proceeds for cancer therapies and development costs.
Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus
04:57am, Friday, 20'th Feb 2026
U.S. stock futures rose on Friday after closing lower on Thursday. Futures of all the major benchmark indices were positive.
Candel Therapeutics prices $100M public offering
03:40am, Friday, 20'th Feb 2026
Candel Therapeutics Inc (NASDAQ:CADL) told investors on Thursday it has priced its previously disclosed public offering of about 18.3 million shares at...
Candel Therapeutics Announces Pricing of Public Offering
09:40pm, Thursday, 19'th Feb 2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering
04:38pm, Thursday, 19'th Feb 2026
Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of its cancer therapy aglatimagene besadenovec (CAN-2409) for intermediate- to
Candel Therapeutics Announces Proposed $100 Million Public Offering
04:05pm, Thursday, 19'th Feb 2026
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
NEEDHAM, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics inks $100M funding agreement with RTW Investments, launches $100M public offering
11:36am, Thursday, 19'th Feb 2026
Candel Therapeutics Inc (NASDAQ:CADL) on Thursday announced two financing initiatives to support the potential US launch of its cancer therapy aglatimagene...
